Hubei Biocause Heilen Pharmaceutical Co., Ltd.
301211.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.97 | 0.64 | 9.57 | -1.85 |
| FCF Yield | -1.62% | -1.14% | 3.05% | 1.65% |
| EV / EBITDA | 29.31 | 11.73 | 22.87 | 27.65 |
| Quality | ||||
| ROIC | 3.93% | 7.46% | 5.51% | 5.39% |
| Gross Margin | 28.84% | 40.17% | 28.88% | 33.72% |
| Cash Conversion Ratio | 1.05 | 0.78 | 1.99 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.69% | 7.04% | -4.59% | 8,146,281.07% |
| Free Cash Flow Growth | -38.18% | -128.29% | 69.89% | -4.96% |
| Safety | ||||
| Net Debt / EBITDA | -4.15 | -7.50 | -10.90 | -11.51 |
| Interest Coverage | 188.76 | 356.31 | 431.83 | 373.86 |
| Efficiency | ||||
| Inventory Turnover | 2.30 | 2.28 | 3.19 | 3.99 |
| Cash Conversion Cycle | 91.14 | 92.96 | 122.34 | 168.38 |